Research programme: trastuzumab biosimilar - Shanghai Fudan-Zhangjiang Bio-PharmaceuticalAlternative Names: Anti-HER2/neu mAb biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical; Fderceptin; Herceptin biosimilar - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Latest Information Update: 06 May 2015
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Class Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 06 May 2015 Preclinical trials in Breast cancer in China (Parenteral), before May 2015